LOVELAND, Colo., March 13, 2012 /PRNewswire/ -- Heska
Corporation ("Heska"; NASDAQ: HSKA), a provider of advanced
veterinary diagnostic and other specialty veterinary products today
announced Diamond Animal Health, Inc. ("Diamond"), a wholly-owned
subsidiary of Heska, will manufacture PetTrust Plus™, a heartworm
preventive product based on an existing FDA approved product.
The product will be sold under an exclusive contractual agreement
to FidoPharmBrands, LLC ("FidoPharm") in the United States.
FidoPharm has received the initial shipment of PetTrust Plus™.
Diamond manufactures vaccine and pharmaceutical products for a
number of animal health companies, all of which are marketed and
sold by third parties under third-party labels. Diamond has
over a fifty (50) year history of quality manufacturing for the
animal health industry.
FidoPharm is responsible for all commercialization
efforts. FidoPharm has the right to sell this product in
retail pharmacies in the United States. A veterinarian's
prescription is required for the purchase of PetTrust Plus™.
About Heska
Heska Corporation (NASDAQ: HSKA) sells advanced veterinary
diagnostic and other specialty veterinary products. Heska's
state-of-the-art offerings to its customers include diagnostic
instruments and supplies as well as single use, point-of-care
tests, pharmaceuticals and vaccines. The Company's core focus
is on the canine and feline markets where it strives to provide
high value products and unparalleled customer support to
veterinarians. For further information on Heska and its
products, visit the company's website at www.heska.com.
Forward-Looking Statements
This announcement contains forward-looking statements
regarding Heska's future financial and operating results.
These statements are based on current expectations and are subject
to a number of risks and uncertainties. In addition, factors
that could affect the business and financial results of Heska
generally include the following: risks related to relying on a
third party to sell and market a given product effectively;
uncertainties regarding Heska and/or Diamond's ability to
manufacture any given product to required specifications including
for regulatory reasons; uncertainties related to the
commercialization of a new product, in particular a new product
sold in a novel manner such as PetTrust Plus™ is intended to be
sold; uncertainties related to Heska's relationship with its
customers and the reaction of such customers to any new product
launch, in particular a product sold in a novel manner such as
PetTrust Plus™ is intended to be sold; competition; and the risks
set forth in Heska's filings and future filings with the Securities
and Exchange Commission, including those set forth in Heska's
Annual Report on Form 10-K for the year ended December 31, 2011.
SOURCE Heska Corporation